Lipid CME
LECTURECMEABIM MOC

Optimizing the Use of PCSK9 Inhibitors for Your Patients

Author(s)/Faculty: Michael H. Davidson, MD, FACC, FACP, FNLA; Daniel E. Soffer, MD, FNLA, FACP; James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Release Date: 5/29/2018Expiration Date: 5/28/2019
Credit Type: CME / ABIM MOCNumber of Credits: 1
Content Type: LectureProvider:
As clinical data emerge regarding the benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, obtaining access to these agents remains a barrier to their use. Given the high prevalence of patients on statin therapy who fail to meet LDL-C target goals, continuing education is crucial regarding the latest clinical advances and recommendations for the use of PCSK9 inhibitors, as well as practical strategies to gain access to these agents to improve patient outcomes. This educational activity will feature a panel of experts who will review the latest recommendations regarding the use of PCSK9 inhibitors and the impact of their use on cardiovascular outcomes. They will also assess the latest data regarding the benefits and safety of achieving low LDL-C goals, as well as detail practical strategies to improve access to treatment. Clinical cases will be presented to highlight the key educational objectives.